Advances in pathogenesis of nonalcoholic fatty liver disease caused by tamoxifen

doi:10.12092/j.issn.1009-2501.2018.06.020

Abstract

Abstract:

Tamoxifen, a selective estrogen receptor antagonist, is most widely used for endocrine therapy for breast cancer. However, mounting evidence suggests that tamoxifen treatment can significantly improve the risk of nonalcoholic fatty liver disease (NAFLD) in breast cancer patients. At present, there is no enough research on hepatic lipotoxicity caused by tamoxifen, the exact mechanism of it is still unknown. In this paper, we reviewed the phenomenon and mechanism of tamoxifen induced nonalcoholic fatty liver disease, providing references for further mechanism research and therapeutic drugs development.

Key words: tamoxifen, endocrine therapy, nonalcoholic fatty liver disease, pathogenesis

CLC Number:

R575.5

CHEN Xi, LING Jiawei, DING Jiaxin, JIANG Zhenzhou, ZHANG Luyong. Advances in pathogenesis of nonalcoholic fatty liver disease caused by tamoxifen[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 715-720.

References

［1］Tremont A, Lu J, Cole JT. Endocrine therapy for early breast cancer: updated review［J］. Ochsner J, 2017, 17(4): 405-411.
［2］替吉奥联合多西他赛治疗转移性乳腺癌的疗效及对血清HER2、VEGF及CA724水平的影响［J］. 空军医学杂志, 2017, 33(1): 33-35.
［3］Lin Y, Liu J, Zhang X, et al. A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer［J］. Cancer Sci, 2014, 105(9): 1182-1188.
［4］Gao FF, Lv JW, Wang Y, et al. Tamoxifen induces hepatotoxicity and changes to hepatocyte morphology at the early stage of endocrinotherapy in mice［J］. Biomed Rep, 2016, 4(1): 102-106.
［5］Yeh WL, Lin HY, Wu HM, et al. Combination treatment of tamoxifen with risperidone in breast cancer［J］. PLoS One, 2014, 9(6): e98805.
［6］Pan HJ, Chang HT, Lee CH. Association between tamoxifen treatment and the development of different stages of nonalcoholic fatty liver disease among breast cancer patients［J］. J Formos Med Assoc, 2016, 115(6): 411-417.
［7］Yan M, Wang J, Xuan Q, et al. The relationship between tamoxifen-associated nonalcoholic fatty liver disease and the prognosis of patients with early-stage breast cancer［J］. Clin Breast Cancer, 2017, 17(3): 195-203.
［8］张霞霞, 徐宏团, 徐有青. 非酒精性脂肪性肝病相关肝硬化的自然史与临床特点［J］. 临床肝胆病杂志, 2018, 34(1): 24-26.
［9］Yang YJ, Kim KM, An JH, et al. Clinical significance of fatty liver disease induced by tamoxifen and toremifene in breast cancer patients［J］. Breast, 2016, 28: 67-72.
［10］AkhondiMeybodi M, Mortazavy-Zadah MR, Hashemian Z, et al. Incidence and risk factors for non-alcoholic steatohepatitis in females treated with tamoxifen for breast cancer［J］. Arab J Gastroenterol, 2011, 12(1): 34-36.
［11］闫永红, 党欢, 宋光辉, 等. 乳腺癌术后他莫昔芬治疗致脂肪肝［J］. 中国新药杂志, 2010, (21): 2016-2018.
［12］Cole LK, Jacobs RL, Vance DE. Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis［J］. Hepatology, 2010, 52(4): 1258-1265.
［13］Gudbrandsen OA, Rost TH, Berge RK. Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver［J］. J Lipid Res, 2006, 47(10): 2223-2232.
［14］Lelliott CJ, Lopez M, Curtis RK, et al. Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis［J］. FASEB J, 2005, 19(9): 1108-1119.
［15］Le TT, Urasaki Y, Pizzorno G. Uridine prevents tamoxifen-induced liver lipid droplet accumulation［J］. BMC Pharmacol Toxicol, 2014, 15: 27.
［16］Gu W, Xu W, Sun X, et al. Anordrin eliminates tamoxifen side effects without changing its antitumor activity［J］. Sci Rep, 2017, 7: 43940.
［17］Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease［J］. J Gastroenterol, 2013, 48(4): 434-441.
［18］Zhao F, Xie P, Jiang J, et al. The effect and mechanism of tamoxifeninduced hepatocyte steatosis in vitro［J］. Int J Mol Sci, 2014, 15(3): 4019-4030.
［19］赵斐, 谢萍, 姜佳丽, 等. 他莫昔芬体外促进HepG2细胞脂肪变性观察［J］. 实用肝脏病杂志, 2014, 16(1): 30-33.
［20］Larosche I, Letteron P, Fromenty B, et al. Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver［J］. J Pharmacol Exp Ther, 2007, 321(2): 526-535.
［21］Birzniece V, Barrett PHR, Ho KKY. Tamoxifen reduces hepatic VLDL production and GH secretion in women: a possible mechanism for steatosis development［J］. Eur J Endocrinol, 2017, 177(2): 137-143.
［22］Zhu L, Brown WC, Cai Q, et al. Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance［J］. Diabetes, 2013, 62(2): 424-434.
［23］Zhang H, Liu Y, Wang L, et al. Differential effects of estrogen/androgen on the prevention of nonalcoholic fatty liver disease in the male rat［J］. J Lipid Res, 2013, 54(2): 345-357.
［24］Han SI, Komatsu Y, Murayama A, et al. Estrogen receptor ligands ameliorate fatty liver through a nonclassical estrogen receptor/liver X receptor pathway in mice［J］. Hepatology, 2014, 59(5): 1791-1802.
［25］Pedram A, Razandi M, O'mahony F, et al. Estrogen reduces lipid content in the liver exclusively from membrane receptor signaling［J］. Sci Signal, 2013, 6(276): ra36.
［26］Wang X, Lu Y, Wang E, et al. Hepatic estrogen receptor alpha improves hepatosteatosis through upregulation of small heterodimer partner［J］. J Hepatol, 2015, 63(1): 183-190.
［27］Zhang ZC, Liu Y, Xiao LL, et al. Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice［J］. J Hepatol, 2015, 63(6): 1466-1475.
［28］Schumacher JD, Guo GL. Mechanistic review of drug-induced steatohepatitis［J］. Toxicol Appl Pharmacol, 2015, 289(1): 40-47.
［29］Ohnishi T, Ogawa Y, Saibara T, et al. CYP17 polymorphism and tamoxifen-induced hepatic steatosis［J］. Hepatol Res, 2005, 33(2): 178-180.
［30］Gonzalez-Cantero J, Martin-Rodriguez JL, Gonzalez-Cantero A, et al. Insulin resistance in lean and overweight non-diabetic Caucasian adults: Study of its relationship with liver triglyceride content, waist circumference and BMI［J］. PLoS One, 2018, 13(2): e0192663.
［31］Gastaldelli A. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD［J］? Clin Sci (Lond), 2017, 131(22): 2701-2704.
［32］Wang XC, Zhan XR, Li XY, et al. Identification and validation co-differentially expressed genes with NAFLD and insulin resistance［J］. Endocrine, 2015, 48(1): 143-151.
［33］赵雄, 范竹萍, 邱德凯, 等. 他莫昔芬对肝细胞胰岛素敏感性的影响［J］. 胃肠病学, 2010, 15(3): 139-142.
［34］Riggins RB, Schrecengost RS, Guerrero MS, et al. Pathways to tamoxifen resistance［J］. Cancer Lett, 2007, 256(1): 1-24.
［35］桑谊荃. 雌激素减少与腹型肥胖和胰岛素抵抗关系的研究进展［J］. 医学综述, 2013, 19(9): 1660-1662.
［36］Ayala A, Munoz MF, Arguelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal［J］. Oxid Med Cell Longev, 2014, 2014: 360438.
［37］Polimeni L, Del Ben M, Baratta F, et al. Oxidative stress: New insights on the association of nonalcoholic fatty liver disease and atherosclerosis［J］. World J Hepatol, 2015, 7(10): 1325-1336.
［38］Albukhari AA, Gashlan HM, El-Beshbishy HA, et al. Caffeic acid phenethyl ester protects against tamoxifen-induced hepatotoxicity in rats［J］. Food Chem Toxicol, 2009, 47(7): 1689-1695.
［39］Suddek GM. Protective role of thymoquinone against liver damage induced by tamoxifen in female rats［J］. Can J Physiol Pharmacol, 2014, 92(8): 640-644.
［40］邹琪婧. 线粒体脂质过载与胰岛素抵抗［J］. 现代医药卫生, 2012, 28(6): 880-882.
［41］Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies［J］. Fundam Clin Pharmacol, 2008, 22(4): 335-353.
［42］Naven RT, Swiss R, Klug-Mcleod J, et al. The development of structure-activity relationships for mitochondrial dysfunction: uncoupling of oxidative phosphorylation［J］. Toxicol Sci, 2013, 131(1): 271-278.
［43］郭瑶雪, 邓晔, 李春, 等. 异烟肼致线粒体损伤引起药物性肝损伤研究进展［J］. 中国临床药理学与治疗学, 2015, 20(3): 356-360.
［44］Theodossiou TA, Yannakopoulou K, Aggelidou C, et al. Tamoxifen subcellular localization; observation of cellspecific cytotoxicity enhancement by inhibition of mitochondrial ETC complexes I and III［J］. Photochem Photobiol, 2012, 88(4): 1016-1022.
［45］Ribeiro MP, Santos AE, Custodio JB. Mitochondria: the gateway for tamoxifen-induced liver injury［J］. Toxicology, 2014, 323: 10-18.
［46］Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis［J］. Free Radic Biol Med, 2012, 52(1): 59-69.

[1]	WANG Chaoyi, SONG Qiang, XIONG Xin, WANG Mengyuan. Research progress on diagnosis and treatment of granulomatous lobular mastitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 910-917.
[2]	WANG Donghui, JIANG Suwen, HU Airong, ZHU Bo, HE Zheyun, ZHANG Lukan, WANG Jialan, FAN Ying, LIN Ken . Mulberry exerts antioxidant stress effect in rats with nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 609-616.
[3]	ZHANG Mingkang, MA Yanrong, JIN Yongwen, ZHOU Yan, CUI Ruirui, WU Xin'an. Advances in clinical research on drug-induced acute interstitial nephritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 419-428.
[4]	WANG Xiu, JI Qilin, PEI Wenjun, ZENG Ying. 3-bromopyruvate cholesterol ester enhances the sensitivity of breast cancer cells to tamoxifen [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1093-1100.
[5]	HUANG Huizhen, HAN Lei, LIN Xiaodong, CHEN Lei. Research progress on signal pathways related to the pathogenesis of pancreatitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 109-113.
[6]	MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling. Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
[7]	MENG Shi, WANG Zhongqun. Research progress on human immunodeficiency virus-associated pulmonary arterial hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1431-1440.
[8]	SONG Ruzheng, PENG Ying, WANG Guangji, SUN Jianguo. Commonly used quantitative proteomics research techniques and their application in the study of pathogenesis of liver-derived diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 570-578.
[9]	CHEN Ying, YUAN Yonggui. Research progress in the treatment of depression with monome of Chinese herb, drug pairs, compound prescriptions and Chinese patent drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 586-593.
[10]	SUN Hong, HOU Jialin, CAI Jiaqin, WEI Xiaoxia, ZHUANG Jie. SUMO E3 ligase mediates androgen receptor transcription to promote tamoxifen resistance of breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 285-291.
[11]	JIN Jing, CHENG Hong. Research progress of mitochondrial energy metabolism involved in the pathogenesis of depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1193-1199.
[12]	ZHOU Yiwen, PING Yi. Research progress on the mechanism and treatment of pelvic organ prolapse [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 595-600.
[13]	ZHAO Quanming, YANG Yang. Progress in drug therapy for advanced triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 475-480.
[14]	WU Min, GUO Yiyun, XIE Haitang. Population pharmacokinetics of tamoxifen in patients with breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 418-423.
[15]	LU Yong-juan, CHEN Zhi-yun, YAN Mao-xiang, HE Bei-hui, ZHU Dan. Effect of atorvastatin on adipokines in rats with nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 520-524.